Aspirin and Other COX-1 Inhibitors

Carlo Patrono, Bianca Rocca

Risultato della ricerca: Contributo in rivistaArticolo in rivista

20 Citazioni (Scopus)


Currently available antiplatelet drugs interfere with the process of platelet activation and aggregation by selectively blocking key enzymes involved in the synthesis of platelet agonists, or membrane receptors mediating activation signals. Pharmacological interference with critical molecular pathways of platelet activation and aggregation may reduce the risk of atherothrombotic complications through mechanisms that are also responsible for an increased risk of bleeding. Acetylsalicylic acid (aspirin) represents a prototypic antiplatelet agent. The aim of this chapter is to integrate our current understanding of the molecular mechanism of action of aspirin with the results of clinical trials and epidemiological studies assessing its efficacy and safety. Moreover, the antiplatelet properties of reversible inhibitors of the same drug target will also be reviewed.
Lingua originaleEnglish
pagine (da-a)137-164
Numero di pagine28
RivistaHandbook Experimental Pharmacology
Stato di pubblicazionePubblicato - 2012


  • aspirin
  • platelet


Entra nei temi di ricerca di 'Aspirin and Other COX-1 Inhibitors'. Insieme formano una fingerprint unica.

Cita questo